Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients.

Färber, L; Stratz, T H; Brückle, W; Späth, M; Pongratz, D; Lautenschläger, J; Kötter, I; Zöller, B; Peter, H H; Neeck, G; Welzel, D; Müller, W

Färber, L; Stratz, T H; Brückle, W; Späth, M; Pongratz, D; Lautenschläger, J; Kötter, I; Zöller, B; Peter, H H; Neeck, G; Welzel, D; Müller, W.

Affiliation

Färber L; Institut für Pharmakologie der Universität Regensburg, Germany.

Int J Clin Pharmacol Res ; 21(1): 1-13, 2001.

Article in En | MEDLINE | ID: mdl-11708570

Subject(s)

Fibromyalgia/therapy; Indoles/therapeutic use; Receptors, Serotonin/drug effects; Serotonin Antagonists/therapeutic use; Adolescent; Adult; Aged; Double-Blind Method; Female; Fibromyalgia/blood; Half-Life; Humans; Indoles/adverse effects; Male; Middle Aged; Pain Measurement; Prospective Studies; Receptors, Serotonin, 5-HT3; Serotonin Antagonists/adverse effects; Tropisetron

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Serotonin Antagonists / Fibromyalgia / Receptors, Serotonin / Indoles Type of study: Clinical_trials / Observational_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Int J Clin Pharmacol Res Year: 2001 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links